NDAORALTABLET, ORALLY DISINTEGRATING
Approved
Feb 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ZOMIG-ZMT (zolmitriptan) by AstraZeneca is serotonin 1b receptor agonists [moa]. Approved for migraine. First approved in 2001.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOMIG-ZMT is an orally disintegrating tablet formulation of zolmitriptan, a serotonin 1B receptor agonist (triptan) approved in 2001 for acute migraine treatment. It works by constricting blood vessels around the brain and reducing substances in the body that cause headache, pain, sensitivity to light and sound, and other migraine symptoms. The ZMT formulation provides rapid absorption without water, offering convenience for migraine patients.
LOE Approaching
Product is in late lifecycle stage with limited growth potential; career opportunities will focus on maintaining market share against newer competitors rather than expansion.
Mechanism of Action
Serotonin 1b Receptor Agonists
Indications (1)
Clinical Trials (2)
Determine Central 5-HT1B Receptor Occupancy of ZOMIG® Rapimelt (Zolmitriptan) in Healthy Male Volunteers
Started May 2010
10 enrolled
Migraine
Efficacy and Tolerability of Zolmitriptan Nasal Spray
Started Sep 2002
2,114 enrolled
Migraine
Career Relevance
Working on ZOMIG-ZMT offers limited career growth opportunities given its LOE-approaching lifecycle and small linked job count (4 roles). Career trajectories favor operational roles (manufacturing, engineering) and business analytics over commercial or medical science advancement.
Worked on ZOMIG-ZMT at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.